Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GPR6 | P46095 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22633593 | 0.81 | RAB9A (0.53) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL458598 | 0.80 | GAA (0.54) | KMT2ARAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL8770282 | 0.74 | MEN1 (0.85) | MEN1KMT2ARAB9ANPC1TDP1 | |
| SCHEMBL22633479 | 0.74 | MAPT (0.58) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8561545 | 0.73 | MEN1 (0.74) | MEN1KMT2ARAB9ANPC1TDP1 | |
| SCHEMBL11729204 | 0.73 | MEN1 (0.80) | MEN1KMT2ARAB9ANPC1TDP1 | |
| SCHEMBL7345883 | 0.73 | MEN1 (0.63) | MEN1KMT2ARAB9ANPC1TDP1 | |
| SCHEMBL2047778 | 0.72 | RAB9A (1.00) | MEN1KMT2ARAB9ANPC1TDP1 | |
| SCHEMBL15154820 | 0.71 | RAB9A (0.61) | MEN1KMT2ARAB9ANPC1TDP1 | |
| SCHEMBL8770663 | 0.71 | NPC1 (0.64) | MEN1KMT2ARAB9ANPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354327-A1 | COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF | CYTUS H&B CO LTD (KR) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354327-A1 | COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF | STAT3, JAK2, STAT6 | MEN1 2656/4885KMT2A 608/4885RAB9A 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.